大剂量甲氨蝶呤作为高危侵袭性B细胞淋巴瘤的中枢神经系统预防
接受大剂量甲氨蝶呤者中枢神经系统进展风险较低(校正HR 0.59),但仅限完成化疗免疫治疗后完全缓解患者时未达统计学显著(校正HR 0.74),5年校正风险差为1.6%(全部患者)和1.4%(完全缓解患者)。结论认为大剂量甲氨蝶呤未带来有临床意义的中枢神经系统进展风险降低。
要点
- 全部患者中接受大剂量甲氨蝶呤者中枢神经系统进展风险较低(校正HR 0.59,95%CI 0.38-0.90,P=0.014)。
- 完全缓解患者中该关联未达统计学显著(校正HR 0.74,95%CI 0.42-1.30,P=0.29)。
- 各高危亚组样本量不足以就大剂量甲氨蝶呤疗效得出确定性结论,但未见明确风险降低。
核心结论
- 在高危侵袭性B细胞淋巴瘤患者中,使用大剂量甲氨蝶呤与中枢神经系统进展风险的降低无临床意义关联。
- 接受大剂量甲氨蝶呤的高危患者2年中枢神经系统进展风险为7.2%,与既往报告的高危队列一致。
研究设计与样本
- 国际性、回顾性、观察性研究,纳入年龄18-80岁、接受以抗CD20为基础的治愈性化疗免疫治疗、中枢神经系统进展高风险的侵袭性B细胞淋巴瘤患者。
- 按是否使用大剂量甲氨蝶呤计算中枢神经系统进展的病因特异性风险比和累积风险;全部患者从诊断起计算至中枢神经系统进展时间,完全缓解患者从完成一线系统性淋巴瘤诱导治疗起计算。
主要发现
- 全部患者中83.4%的中枢神经系统国际预后指数为4-6分。
- 全部患者中,接受大剂量甲氨蝶呤者中枢神经系统进展风险较低(校正HR 0.59,95%CI 0.38-0.90,P=0.014)。
- 完全缓解患者中,该关联未达统计学显著(校正HR 0.74,95%CI 0.42-1.30,P=0.29)。
- 5年校正风险差:全部患者为1.6%(95%CI -1.5至4.4),完全缓解患者为1.4%(95%CI -1.5至4.1)。
- 各高危亚组样本量不足以就大剂量甲氨蝶呤在个体高危临床场景中的疗效得出确定性结论,但任何高危亚组中均未见大剂量甲氨蝶呤明确降低中枢神经系统进展风险。
局限性
- 各高危亚组样本量不足以就大剂量甲氨蝶呤在个体高危临床场景中的疗效得出确定性结论。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexate (HD-MTX) is effective at preventing CNS progression in patients at high risk of this complication. PATIENTS AND METHODS: Patients age 18-80 years with aggressive B-cell lymphoma and high risk of CNS progression, treated with curative-intent anti-CD20-based chemoimmunotherapy, were included in this international, retrospective, observational study. Cause-specific hazard ratios (HRs) and cumulative risks of CNS progression were calculated according to use of HD-MTX, with time to CNS progression calculated from diagnosis for all patients (all-pts) and from completion of frontline systemic lymphoma induction therapy, for patients in complete response at completion of chemoimmunotherapy (CR-pts). RESULTS: Two thousand four hundred eighteen all-pts (HD-MTX; n = 425) and 1,616 CR-pts (HD-MTX; n = 356) were included. CNS International Prognostic Index was 4-6 in 83.4% all-pts. Patients treated with HD-MTX had a lower risk of CNS progression (adjusted HR, 0.59 [95% CI, 0.38 to 0.90]; P = .014), but significance was not retained when confined to CR-pts (adjusted HR, 0.74 [95% CI, 0.42 to 1.30]; P = .29), with 5-year adjusted risk difference of 1.6% (95% CI, -1.5 to 4.4; all-pts) and 1.4% (95% CI, -1.5 to 4.1; CR-pts). Subgroups were underpowered to draw definitive conclusions regarding the efficacy of HD-MTX in individual high-risk clinical scenarios; however, there was no clear reduction in CNS progression risk with HD-MTX in any high-risk subgroup. CONCLUSION: In this large study, high-risk patients receiving HD-MTX had a 7.2% 2-year risk of CNS progression, consistent with the progression risk in previously reported high-risk cohorts. Use of HD-MTX was not associated with a clinically meaningful reduction in risk of CNS progression.
引用
- Lewis KL, Jakobsen LH, Villa D, et al. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. J Clin Oncol. 2023. PMID: 37797284. doi:10.1200/JCO.23.00365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。